Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

400.16 -1.98 (-0.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
41 42 Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
Upgrades 
Via Benzinga
ViaCyte Acquisition Can Accelerate Vertex's Ongoing Type 1 Diabetes Programs
Via Benzinga
Why Top-Notch Biotech Stock Vertex Pharmaceuticals Just Hit A Record
The stock hit its highest point in decades Wednesday on key FDA action. 
Via Investor's Business Daily
FDA Lifts Clinical Hold On Vertex Pharma's Stem Cell Derived Diabetes Treatment Trial
Via Benzinga
The 3 Leaders of the Gene Editing Revolution
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say. 
Via Investor's Business Daily
Analyzing Vertex Pharmaceuticals's Short Interest
Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has fallen 11.26% since its last report. The company recently reported that it has 3.42 million shares sold short,... 
Via Benzinga
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91. 
Via Investor's Business Daily
FDA Lifts Clinical Hold On Vertex's Initial-Stage Diabetes Study
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on Vertex Pharmaceuticals’ (NASDAQ: VRTX) Phase 1/2 clinical trial of VX-880 for patients with type 1 diabetes (T1D). 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Amphastar Pharmaceuticals Stock Scores Composite Rating Climb To 96
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before. 
Via Investor's Business Daily
Kura Oncology Stock Scores Rising Relative Strength
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier. 
Via Investor's Business Daily
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92
Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before. 
Via Investor's Business Daily
Why Jim Cramer Prefers Devon Energy Over EOG Resources
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Devon Energy Corporation (NYSE: DVN) over EOG Resources, Inc. (NYSE: EOG) as the former is cheaper. 
Via Benzinga
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year. 
Via Investor's Business Daily
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money
With an economic hurricane on the horizon, investors are searching for alternative investment paths and profitable places to invest in. 
Via InvestorPlace
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 8.19% on an annualized basis producing an average annual return of 15.06%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade
Day One Biopharmaceuticals stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 83 to 92. 
Via Investor's Business Daily
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
Crispr and Vertex tested their gene-edited drug in two blood diseases. 
Via Investor's Business Daily
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic... 
Via Benzinga
Expert Ratings for Vertex Pharmaceuticals
Over the past 3 months, 8 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing
The company is using a different approach to tackle the blood disease. 
Via Investor's Business Daily
7 of the Hottest ETFs to Buy Right Now
These are the hottest ETFs to buy in June whether you're looking for discounts or ETFs that are already on the move. 
Via InvestorPlace
Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark
On Wednesday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 66 to 75. 
Via Investor's Business Daily
Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82
Looking for the best stocks to buy? Focus on those with rising relative price strength, such as Regeneron Pharmaceutical stock. 
Via Investor's Business Daily
Vertex Pharma Gains FDA Breakthrough Therapy Designation For Kidney Disease Drug
Vertex Pharmaceuticals (NASDAQ: VRTX) received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate inaxaplin (VX-147) for the treatment of patients... 
Via Benzinga
7 Oversold Stocks to Buy Right Now
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price. 
Via InvestorPlace
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
41 42 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.